-
ESMO 2022 Professor Dongliang Yu: Incidence of EGFR mutation and disease prognosis in patients with locally resectable NSCLC in the real world
Time of Update: 2023-01-05
2Study designThe main inclusion criteria for the EXERPOS-GFPC study were: patients with local NSCLC who underwent continuous surgery in France from January 2018 to December 2019, and the study collected data including demographic and clinical data, type of surgery, stage, disease recurrence, and treatment in case of disease recurrence.
-
Certain clinicopathological and molecular predictors in combination with PD-L1 expression can help select the most appropriate IO-based first-line therapy for patients with advanced non-small cell lung cancer
Time of Update: 2023-01-05
(If you need the original text, you can add the editor WeChat yxj_oncology to get) Scan the QR code above to get more cutting-edge information1J Natl Cancer Inst: Certain clinicopathological and molecular predictors in combination with PD-L1 expression can help select the most appropriate IO-based first-line therapy for patients with advanced non-small cell lung cancer▎ Clinical problems: immunotherapy (IO) Many NSCLC patients do not benefit well.
-
Latest research: people with diabetes are more likely to develop cancer, especially advanced cancer!
Time of Update: 2023-01-05
Image source: 123RFPeople from the World Health Organization's International Agency for Research on Cancer (IARC) and other organizations analyzed data from the European Prospective Survey on Cancer and Nutrition (EPIC) and included 400577 participants who joined the study without cancer and cardiometabolic diseases, including cardiovascular disease and type 2 diabetes。 The researchers collected basic information such as the participants' height and weight; Lifestyle information such as smoking status, alcohol consumption, diet, sleep, etc.
-
Prognostic significance of HER2 low expression in patients with HR-positive early-stage breast cancer
Time of Update: 2023-01-05
A total of 949 patients with HR-positive/HER2-negative breast cancer were enrolled, and the results showed that low expression of HER2 in patients with HR-positive breast cancer did not affect prognosis, but may lead to shortened recurrence-free survival (DFS) in patients with invasive lobular carcinoma and invasive breast ductal/lobular carcinoma, as well as patients with HER2 2+ and node-positive lymph nodes.
-
Brainstorming, tumor-related anemia/tumor-related thrombocytopenia special session to explore the whole process of management standards 2022 CSCO academic annual meeting Harbin branch
Time of Update: 2023-01-05
Thinking, communicating, summarizing, and seeking development are the driving forces for the development of medicine, and they are also the habits that doctors in the field of blood have adhered to fo
-
It was reported by CCTV that the strongest anti-cancer monomer to treat tumors has these benefits!
Time of Update: 2023-01-05
In the past half century, the medical treatment of cancer is also diverse, with the development of medical technology, new drug development and medical detection methods iteration, the survival time o
-
The latest data of the two drugs are announced! Oncolytic virus has become a heavy weapon to treat the "king of brain cancer"?
Time of Update: 2023-01-05
November 22, 2022 / eMedClub News / -- On November 18, 2022, Oncorus and Candel Therapeutics announced the latest data on oncolytic virus therapy at the 27th annual meeting of the Society of Neuro-Onc
-
Express significantly improves overall survival for advanced gastric cancer! Keytruda combination therapy meets the primary endpoint of the Phase 3 trial
Time of Update: 2023-01-05
▎WuXi AppTec content team editorMerck (MSD) today announced the positive top-line results of its blockbuster immunotherapy Keytruda (pembrolizumab) combination therapy in the treatment of gastric cancer.
▎WuXi AppTec content team editorMerck (MSD) today announced the positive top-line results of its blockbuster immunotherapy Keytruda (pembrolizumab) combination therapy in the treatment of gastric cancer.
-
Professor Zhou Caicun CameL research: The co-expression of different tumor immune microenvironment markers has the predictive value of potential immune combination therapy
Time of Update: 2023-01-05
Fig. 4 Tumor mutation characteristics of CD8/PD-L1 co-expression positive and negative groups3smallknotThis study mainly explores the predictive value of the expression levels of tumor immune microenvironment biomarkers PD-L1, CD8, CD68, CD4, FOXP3 and their different combinations in patients with locally advanced or metastatic NSCLC treated with PD-1 inhibitors and chemotherapy.
-
Nearly 60% of patients are terminal! How can liver cancer research be "tailored" for Chinese patients?
Time of Update: 2023-01-05
In terms of liver cancer treatment drugs, immunotherapy represented by PD-1 monoclonal antibody is changing the diagnosis and treatment pattern of middle and advanced liver cancer, and bringing breakthroughs to prolong the survival of liver cancer patients.
-
49% reduction in risk of disease progression! Discover new genes that predict colorectal cancer treatment outcomes!
Time of Update: 2023-01-05
Recently, a research team performed whole exome sequencing on the discovery cohort of mCRCBRAF-V600E patients receiving anti-BRAF/EGFR therapy, and found that the inactivation mutation of the negative regulator of WNT, RNF43, predicted improved response rate and survival outcomes in patients with microsatellite stable (MSS) tumors.
-
The latest research finds new strategies to enhance oncolytic virus therapy and promote long-term anti-tumor immunity!
Time of Update: 2023-01-05
e. , in situ inoculation (ISV), which eliminates the need to predetermine tumor Ag. Researchers have previously demonstrated that effective ISVs can be achieved by mobilizing DC with the Flt3 ligand (Flt3L), radiation therapy to release tumor Ag and load DC, and TLR agonist (TLRa) to activate Ag-loaded DC.
-
61% lower risk of cancer! Harvard research shows that changing these three lifestyles can be done
Time of Update: 2023-01-05
(Click above to view the detailed schedule)This article is the original of Translational Medicine Network, please indicate the source for reprintingWritten by JevinThe incidence of most cancers increases significantly with age, and cancer is the second leading cause of death in older adults, so cancer is considered a major age-related disease in the United States and Europe.
-
Nature Nanotechnol| novel nanocarrier co-loaded platinum drugs and Xkr8 siRNA for improving tumor microenvironment
Time of Update: 2023-01-05
On November 24, 2022, Chen Heang, a doctoral student in Professor Li Song's research group at the University of Pittsburgh School of Pharmacy, and other researchers published an article in Nature Nanotechnology Targeting Xkr8 via nanoparticle-mediated in situ codelivery of siRNA and chemotherapy drugs for cancer immunochemotherapy。 The authors found that Xkr8 in tumor cells was significantly highly expressed after platinum treatment, and then developed a novel nanocarrier that can co-carry platinum drugs and Xkr8 siRNA.
-
For the treatment of advanced non-small cell lung cancer, AstraZeneca PD-1/TIGIT bispecific antibody initiates phase 2 clinical trial
Time of Update: 2023-01-05
▲If you have any business needs, please press and hold to scan the QR code above, or▎WuXi AppTec Content Team Editor Recently, AstraZeneca launched a Phase 2 clinical trial for its PD-1/ The TIGIT bispecific antibody AZD2936 was evaluated for its efficacy and safety in the treatment of patients with stage 3 unresectable or stage 4 non-small cell lung cancer (NCSLC).
-
Therapeutic strategies and key issues for HER2-low expression breast cancer
Time of Update: 2023-01-05
*For medical professionals onlyAfter the release of the DB04 study, where will the path of individualized treatment of HER2 low expression lead?The advent of new ADC drugs breaks the traditional wisdom that for more than 20 years only patients with HER2-positive breast cancer can benefit from anti-HER2-targeted therapy.
-
ESMO Metastatic Colorectal Cancer Guidelines Updated! Figure 5 Table 9 shows "state-of-the-art"~
Time of Update: 2023-01-05
The Medical Oncology Channel has specially compiled this "state-of-the-art" guide into a chart, which is convenient for you to view ~ screenshot of the first page of the guide1Diagnostic, pathology, and molecular biology Adequate radiographic imaging and histologic examination of the primary tumor or metastases should always be performed prior to any treatment to confirm clinically or biologically suspicious mCRC.
-
Express "smell" to know if you have cancer? Early pancreatic cancer risk assessment tool is available
Time of Update: 2023-01-05
▲If you have any business needs, please press and hold to scan the QR code above, or▎WuXi AppTec Content Team Editor Recently, Hirotsu Bio Science announced the successful launch of an innovative pancreatic cancer early screening product, according to the company's press release, this is the world's first test kit that uses nematodes for early pancreatic cancer screening.
-
Workflow of TCR-T cell therapy
Time of Update: 2023-01-04
Preclinical safety testing is also necessary to ensure minimal off-target effects and cross-reactivity of isolated high-affinity TCRs. Viral vectors are commonly used to genetically modify autologous patient T cells to express validated therapeutic TCR before being transfused back into the patient.
-
European Radiology: radioprognostic factors for synovial sarcoma of the extremities
Time of Update: 2023-01-04
However, these clinical, pathological, and imaging PFs have not been independently studied in large populations of patients with long-term follow-up.
005) were independent PFs of OS。 A 40-year-old patient with SS grade 3 FNCLCC shows a "triad" (A) on T2WI and no calcifications on CT scan (B).
